Log In
Print this Print this

Xigduo (Dapagliflozin/metformin)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionCombination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation EU - Standard Review (Treat Type II diabetes)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today